本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
HONG KONG SAR - Media OutReach Newswire - 8 July 2025 - AIA Hong Kong announces the launch of the GlobalFlexi Savings Insurance Plan (the Plan). Designed to meet the needs of customers seeking financial flexibility and long-term wealth accumulation, the Plan offers a projected total internal rate of return (IRR) of up to 6.5%# by the end of the 30th policy year. It introduces rare-in-market* features, including Flexi Withdrawal Option and Value Safeguard Option, which enable flexible cash withdrawals to enhance liquidity while accumulating wealth. Additionally, the Plan includes the market-first^ Health Impairment Option, providing added security for the loved ones during times of uncertainty. Alice Liang, Chief Proposition & Healthcare Officer of AIA Hong Kong & Macau Ms Alice Liang, Chief Proposition & Healthcare Officer of AIA Hong Kong & Macau, said, "At every stage of life, financial resilience is key to empowering individuals to pursue their aspirations and confidently navigate unforeseen challenges. For example, many parents aspire to support their children in studying abroad at prestigious universities – a goal that often involves significant financial commitments and uncertainties, such as exchange rate fluctuations. Prudent planning and choosing a flexible wealth solution are therefore essential. AIA understands these evolving needs, which is why we have introduced the new GlobalFlexi Savings Insurance Plan. Thoughtfully designed, it empowers customers with financial clarity and provides peace of mind for their loved ones." She added: "Rooted in Asia for over a century, AIA remains committed to its customer-centric approach, offering innovative and reliable propositions that support individuals through every life stage and aspiration. We are dedicated to helping our customers live Healthier, Longer, Better Lives, enabling them and their loved ones to accomplish their dreams." Key features of the GlobalFlexi Savings Insurance Plan: Wealth Accumulation & Liquidity Projected break-even period as short as seven years%, with a competitive projected IRR of up to 6.5% by the end of the 30th policy year#. Rare-in-market Flexi Withdrawal Option* enables customers to withdraw policy values regularly as needed and designate a loved one as the recipient. Rare-in-market Value Safeguard Option* allows customers to withdraw and transfer cash value while earning non-guaranteed interest, providing liquidity for near-term life goals. Market-first Currency Exchange Option^ enables policyholders to switch among nine different currencies&, facilitating diversified asset allocation. Addressing Health & Future Challenges Market-first Health Impairment Option^ provides financial protection and policy ownership transfer arrangements if the policyholder loses capacity due to a mental issue or a specified illness including Apallic Syndrome and Coma, ensuring financial stability for the family. To further support customers in preparing their children for a successful future, AIA has partnered with a professional education consulting institution from 1 July to 31 December 2025 to provide GlobalFlexi Savings Insurance Plan customers with exclusive privileges. These include overseas education strategy seminars, consultancy on further studies, personalised education roadmap, tutoring and interview coaching. This partnership equips parents and students with the tools to navigate global education trends confidently and plan ahead. As part of its latest campaign for the GlobalFlexi Savings Insurance Plan, AIA has enlisted Michelle Wai, one of its Rethink Healthy Ambassadors and a seven-time award-winning actress, to embody the product spirit. In the advertising video, Michelle reflects on her acting career, highlighting perseverance and resilient — values that align with AIA's enduring commitment to its customers. The campaign debuted on 8 July 2025 across major promotional platforms in Hong Kong, including the latest prime locations such as MTR Kai Tak Station and Sung Wong Toi Station. AIA Rethink Healthy Ambassador and 7-time award-winning actress Michelle Wai stars in the new GlobalFlexi Savings Insurance Plan campaign [Watch the campaign video by clicking here] AIA Group is the largest independent publicly listed pan-Asian life insurance group, with over 600 investment employees1 across the Asia Pacific. AIA Hong Kong has ranked No. 1 in the number of new business policies in Hong Kong for 11 consecutive years2 and has been named Hong Kong's Most Popular Insurance Brand for nine straight years3, a testament to the trust and support of its customers. All information above is for reference only and does not constitute any offer and/or insurance product recommendation. The product information in this material does not contain the full terms of the product, for the details of the product features, terms and conditions, exclusions and key product risks, please refer to the product brochure and policy contract of relevant products or visit the AIA Hong Kong's website. Remarks * Multiple rare-in-market features Flexi Withdrawal Option: Compared with the savings insurance products provided by Hong Kong major insurance companies as of 23 June 2025. Velue Safeguard Option: Compared with the savings insurance products provided by Hong Kong major insurance companies as of 23 June 2025. ^ Multiple market-first features Currency Exchange Option: Pioneered by AIA in the Global Power Multi-Currency Plan on 1 June 2021. Health Impairment Option: This option allows the policy owner to designate up to 2 different designated recipients and elect for both benefit payment and transfer of ownership at the same time. This feature is first-in-market when compared with the savings insurance products provided by Hong Kong major insurance companies, pioneered by AIA with the Wealth Generation life insurance plan on 23 June 2025. # Illustrative case example: assuming a policyholder purchases the GlobalFlexi Savings Insurance Plan with a 5-year premium payment, annual premium of US$100,000, total premiums of US$500,000. This is a hypothetical example for illustrative purposes only. Actual bonuses and dividends are not guaranteed and determined solely at AIA’s discretion. The total IRR does not represent future performance and is non-guaranteed. In the worst-case scenario, the actual total IRR by the end of the 30th policy year may be equal to the guaranteed IRR of 3.48%. % “Projected total breakeven period” is the policy year at the end of which the projected total surrender value is greater than or equal to the single premium paid for the first time. Illustrative case example: assuming a policyholder purchases the GlobalFlexi Savings Insurance Plan with a 5-year premium payment, annual premium of US$100,000, total premiums of US$500,000. In the worst-case scenario, the projected break-even period is by the end of the 18th policy year. Expected breakeven periods and total IRR vary by premium payment method. Single premium payments may achieve an expected breakeven period as short as 5 years. Expected breakeven periods are not guaranteed. Single premiums are invested once across diversified assets per strategy, while 5-year premium plans invest in five tranches any may benefit from dollar-cost averaging. In comparison, single premium payment policies may experience greater investment volatility with wider fluctuations in projected bonuses and dividends. In the worst-case scenario, the actual total IRR may be equal to the guaranteed rate. & Starting from the end of the 2nd policy year and within 30 days after the end of a policy year, you may apply once per policy year to switch your policy currency to one of the following 9 different currencies, including Renminbi (RMB), British pound sterling (GBP), US dollar (US$), Australian dollar (AUD), Canadian dollar (CAD), HK dollar (HK$), Macau pataca (MOP; only for policies issued in Macau), Euro (EUR) and Singapore dollar (SGD), by exchanging your GlobalFlexi Savings Insurance Plan policy for the latest plan under the GlobalFlexi Series which we offer in the new policy currency at the time of currency exchange. The approval of Currency Exchange Option’s application and the availability of currency for selection at the time of exercising the Currency Exchange Option will be subject to the prevailing laws and regulations, and our prevailing rules and conditions. 1. As of 31 December 2024 2. Based on statistics from Insurance Authority released since 2014 - Provisional statistics of the Insurance Authority on Hong Kong long-term insurance business for full year 2014-2024. 3. According to YouGov, an international research and data analytics company, Hong Kong BrandIndex 2016-2024. AIA has been the Top Insurance Brand in Brand Consideration and Most Likely to Purchase in Hong Kong for nine consecutive years since 2016. Hashtag: #AIA #友邦The issuer is solely responsible for the content of this announcement.About AIA Hong Kong & MacauAIA Group Limited established its operations in Hong Kong in 1931. To date, AIA Hong Kong and AIA Macau have over 18,000 financial planners1, as well as an extensive network of independent financial advisors, brokerage and bancassurance partners. We serve over 3.6 million customers2, offering them a wide selection of professional services and products ranging from individual life, group life, accident, medical and health, pension, personal lines insurance to investment-linked assurance schemes with numerous investment options. We are also dedicated to providing superb product solutions to meet the financial needs of high-net-worth customers. 1 As of 31 March 2025 2 Including AIA Hong Kong and AIA Macau's individual life, group insurance and pension customers (as of 31 March 2025)
SINGAPORE - Media OutReach Newswire - 26 March 2025 - A revolutionary case study and scientific research have revealed that INDIBA 448 kHz monopolar radiofrequency technology offers a highly effective and non-invasive approach to reducing visceral fat deposits and preventing new fat cell formation. These findings position INDIBA as a leading solution in aesthetic body contouring and fat management, inspiring beauty, wellness, and aesthetic professionals to rethink conventional fat-reduction strategies. Revolutionizing Fat Reduction and Prevention Unlike traditional fat-reduction treatments such as liposuction, cryolipolysis, and laser lipolysis—which focus on eliminating existing fat—INDIBA's 448 kHz radiofrequency technology takes a proactive approach by targeting fat accumulation at its source. Instead of merely removing fat cells, INDIBA actively interferes with their formation at a cellular level, offering a scientifically backed, non-invasive solution for long-term fat management. Visceral fat, the type that accumulates around internal organs, is known to be a significant contributor to serious health conditions, including cardiovascular disease, type 2 diabetes, and metabolic syndrome. While reducing visceral fat has traditionally been difficult without invasive intervention, INDIBA's advanced radiofrequency technology provides a safe and effective alternative. Case Study Conducted at Onomura Clinic, Tokyo In a case study conducted at Onomura Clinic, Tokyo, Japan, the effects of INDIBA 448 kHz radiofrequency were evaluated on three individuals with varying levels of visceral fat accumulation. Key Findings: Patient 1: A 36-year-old female underwent five 20-minute sessions, achieving a 45% reduction in visceral fat, with an additional 2 kg weight loss. Patient 2: A 42-year-old female completed eight sessions, resulting in a 38.3% reduction in visceral fat and a 2.9 kg weight loss. Patient 3: A 50-year-old male received thirteen sessions over 17 days, achieving a 21% reduction in visceral fat and a 3.3 kg weight loss. These results were verified through CT scan and weight measurement, demonstrating significant reductions in visceral fat deposits following treatment. Case Study Highlights INDIBA 448 kHz Radiofrequency’s Role in Visceral Fat Reduction and Prevention of Fat Accumulation Scientifically Validated Anti-Adipogenic Effects In addition to these clinical outcomes, scientific research published in Molecular Medicine Reports (2016) further supports INDIBA's anti-adipogenic effects. The study, conducted by Dr. Hernández-Bule, Dr. Alejandro Úbeda, and colleagues, demonstrated that subthermal (non-heated) radiofrequency exposure at 448 kHz significantly inhibits the differentiation of human mesenchymal stem cells (hMSCs) into adipocytes—the cells responsible for fat storage. INDIBA's technology has been shown to reduce fat storage by up to 61%—before it even has a chance to form. That means you can achieve a slimmer, more contoured body without the need for invasive procedures. INDIBA's technology targets the key gene responsible for fat storage, effectively 'switching it off' and preventing fat from forming in the first place. Activation of the MEK1/2 pathway, which blocks a key process needed for fat cells to fully form, making it harder for the body to store fat. This mechanism confirms that INDIBA not only reduces existing fat but also prevents the formation of new fat cells, offering a comprehensive solution to fat management and body contouring. Read the original study here. How INDIBA 448 kHz Works: A Non-Invasive Approach to Fat Reduction and Prevention INDIBA's radiofrequency technology delivers three key physiological actions that work synergistically to reduce fat and support tissue health: Biostimulation – Promotes cellular metabolism and fat breakdown while enhancing tissue regeneration. Vascularization – Improves blood flow, aiding in detoxification and nutrient delivery to support fat metabolism. Hyperactivation – Accelerates metabolic activity, facilitating the body's natural fat-reduction processes and preventing new fat accumulation. INDIBA not only delivers longer-lasting results but also eliminates the risks of surgical procedures, such as scarring, infection, and prolonged recovery times. With zero downtime, it offers a safe and effective solution for sustainable body contouring and visceral fat reduction. Transforming Beauty and Wellness Practices For aesthetic doctors, beauty and wellness professionals, and medical spas, INDIBA 448 kHz represents a next-generation, evidence-based solution that aligns with the increasing demand for non-invasive, effective, and scientifically validated fat management treatments. The ability to reduce visceral fat, prevent fat cell formation, and support skin tightening and tissue regeneration makes INDIBA a versatile treatment option. It is suitable as a standalone therapy or as an adjunctive treatment to enhance the results of other body-contouring procedures. Looking Ahead This research and case study reinforce INDIBA's position as a leader in non-invasive fat management technology. As the industry moves toward more holistic and preventative health and wellness solutions, INDIBA's 448 kHz radiofrequency stands out for its scientific validation, clinical efficacy, and commitment to safety. For more information about INDIBA 448 kHz technology and partnership opportunities, visit www.indibasia.com. Hashtag: #INDIBAThe issuer is solely responsible for the content of this announcement.About INDIBA With over 40 years of expertise in radiofrequency technology, INDIBA is a global leader in non-invasive beauty, wellness, and clinical recovery solutions. Headquartered in Barcelona, Spain, INDIBA continues to set industry standards through innovative technologies that empower healthcare professionals and improve lives worldwide. INDIBA Asia Headquarters is based in Singapore.
On July 7, Wanka Online Inc. (01762.HK), a leading technology-driven marketing company in China’s mobile internet sector, held a strategic press conference in Shenzhen. At the event, it officially launched its “AI + Global Expansion: Advancing Toward a RMB 10 Billion Revenue Goal” strategy. Centered on overseas mobile marketing growth, the rapid growth of AI-powered applications, and the development of AI-driven data services, the strategy combines organic expansion with strategic acquisitions to reach RMB 10 billion in annual revenue by 2029. The company is accelerating its transformation through full adoption of AI. Its goal is to become a global provider of intelligent services with core competencies in AI data solutions, AI data infrastructure standardization, and vertical-specific AI agents. For years, Wanka Online has offered integrated services such as mobile advertising and content distribution to smartphone makers, advertisers, and developers. It has built deep expertise in game marketing and serves top brands like Apple, Huawei, Xiaomi, OPPO, vivo, and Honor. Through the channels of terminal manufacturers, it connects businesses with over 2 billion smart device users worldwide. Over the past decade, Wanka Online has become China’s leading player in the game advertising sector based on smartphone application stores, holding over 50% market share. This leadership has allowed it to build vast datasets and strong technical capabilities. By integrating advanced AI algorithms and large models, it developed an AI-powered autonomous marketing platform. Through continuous data iteration and model optimization, the company has built an intelligent closed-loop system involving data accumulation, AI algorithm learning, data analytics, and autonomous decision-making, significantly enhancing advertising precision and boosting marketing ROI. Looking ahead, the company will continue to increase investment in R&D. It expects the total volume of data processed by its AI technology platform to reach the hundreds of billions. Wanka Online plans to expand three core modules: an AI advertising engine, an AI creative engine, and an AI agent service suite, offering advertisers a one-stop digital marketing solution. As AI evolves, Wanka Online sees AI-powered smart terminals—capable of high-efficiency computing, real-world perception, autonomous learning, and content generation—as the next major technological shift in the coming decade. In response, it is boosting investment in AI R&D. In the short term, it is benchmarking leaders like AppLovin to launch AI-driven mobile marketing services and expanding into AI data processing while exploring use cases and commercial models for Quick Apps. In the medium term, Wanka Online plans to work closely with smartphone manufacturers to establish AI data access standards and build a standardized AI interface, laying the foundation for an intelligent marketing ecosystem. In the long term, it aims to enter the AI agent market and collaborate with smartphone manufacturers to develop a robust AI terminal ecosystem, targeting well-defined industries as strategic entry points. Global expansion is the second pillar of its dual-engine strategy. In 2024, the company began expanding overseas, leveraging smartphone manufacturers’ international traffic and partnerships while entering new global media channels to create fresh revenue streams. Wanka Online has set a clear roadmap for future growth. While maintaining steady performance in traditional advertising, it expects rapid growth in global operations, AI-driven marketing services, and AI data solutions. Management forecasts a compound annual growth rate of around 30%, aiming for RMB 10 billion in revenue by 2029. With its “AI + Global Expansion” strategy, the company seeks to scale operations and maximize long-term value for shareholders. - END - About Wanka Online: Wanka Online Inc. (01762.HK) is a publicly listed technology marketing company in the mobile internet sector. Committed to becoming a trusted partner in intelligent services, it provides integrated mobile ecosystem services such as commercial advertising and content distribution to smartphone manufacturers and content developers. Wanka Online is a key ecosystem partner and core service provider to major smartphone brands such as OPPO, vivo, Huawei, Xiaomi, Honor, and Apple (in no particular order), reaching over 90% of mobile users in the market. It has developed an intelligent commercialization service platform to deliver tailored marketing and advertising solutions.
SunJoy Global Insurance Plan II, SunGift Global Insurance Plan II and Stellar Multi-Currency Insurance Plan II offer market-leading flexible Death Benefit Settlement Solution, multiple Contingent Policy Owner Arrangement and Interim Policy Owner ArrangementHONG KONG SAR - Media OutReach Newswire - 3 July 2025 - Sun Life today announced the launch of an upgraded suite of savings insurance products. The upgraded products – SunJoy Global Insurance Plan II, SunGift Global Insurance Plan II, and Stellar Multi-Currency Insurance Plan II – are among Sun Life's most popular offerings. Key enhancements include the introduction of a market-leading1 mix of multiple Death Benefit Settlement Options, multiple Contingent Policy Owner2 and Interim Policy Owner Arrangement2. These upgrades are designed to help Clients capture wealth growth while seamlessly planning their wealth legacy. Christine Yeung, General Manager, Life and Health of Sun Life Hong Kong Limited, said: "At Sun Life, we're committed to putting our Clients at the centre of everything we do. We understand their evolving needs in wealth accumulation and legacy planning for both the present and the future. The innovative and flexible design of the SunJoy Global and SunGift Global series, along with the Stellar Multi-Currency Insurance Plan, plays a pivotal role in helping Clients shape their wealth legacy and meet increasingly diverse needs. These three upgraded savings insurance plans are equipped with brand-new wealth legacy features, empowering Clients to achieve their financial goals while offering unparalleled flexibility in passing on their wealth to future generations. Moving forward, we will continue to drive product innovation, offering pioneering protection and wealth planning solutions to help the public achieve lifetime financial security." The three upgraded savings plans are participating insurance plans. The two major enhancements include: Market-leading flexible Death Benefit Settlement Option Policy owners can mix and match multiple death benefit payout patterns with a Flexible Option, moving beyond package-based death benefit payment options. Policy owners can design their own payout patterns for each beneficiary or choose a designated lump-sum payout upon designated life events of the beneficiary – such as graduating from university, getting married or having a child. If the Designated Insured passes away, the Continuation Option3,4 allows the Original Policy to immediately terminate and a New Policy to be formed, with a beneficiary becoming both the New Insured and the new policy owner5 (if applicable). Market-rare multiple Contingent Policy Owner Arrangement and Interim Policy Owner Arrangement Policy owners can designate up to three Contingent Policy Owners and designate up to three Interim Policy Owners for one of the Contingent Policy Owners6 in sequence, ensuring the policy's value and wealth is seamlessly passing on to future generations. Interim Policy Owners will hold the policy on behalf of the Contingent Policy Owner until he/she attains the designated age or until the specified date is reached. They will have Restricted Administrative Rights to manage the policy, ensuring the wealth is transferred according to the policy owner's plan. The product upgrades enable Clients to tailor their wealth management and legacy plans according to their needs. The plans offer a variety of protections targeting different life stages, helping Clients cope with unexpected challenges, including: Upgraded Product Features Early Value Lock-in Option7: Starting from the 5th policy anniversary, the policy owner can apply to transfer 10%-50% of the policy's value to the Value Lock-in Account each policy year. Whole life protection: The benefit term is extended to the whole life of the current insured (for single life) or the younger insured (for joint life). Enhanced Guaranteed Death Benefit: 105%*/105%-120%** of total premium paid. [*Only applicable to SunJoy Global Insurance Plan II and SunGift Global Insurance Plan II] [**Only applicable to Stellar Multi-Currency Insurance Plan II] Extended Incapacity Benefit coverage8: In addition to being diagnosed as mentally incapacitated, policy owners diagnosed with coma9, major head trauma10 or paralysis11 can have a family member appointed as the Incapacity Benefit Recipient to file a claim. Extended Waiver of Premium Benefit: If the insured, who is also the policy owner, is diagnosed as suffering from Total Permanent Disability due to Injury or Sickness before age 70, Client can enjoy Waiver of Premium Benefit12. If the policy owner, who is not the insured, passes away or is diagnosed as suffering from Total Permanent Disability before age 70 due to Injury or Sickness, Client can enjoy Payor Benefit12. Academic Achievement Awards: An award is paid based on the insured's academic achievement in the Hong Kong Diploma of Secondary Education Examination, TOEFL, IELTS, International Baccalaureate Diploma Program, Mainland Gaokao, SAT, or upon receiving an unconditional offer of admission to a full-time undergraduate program of the world's top 10 universities. [Only applicable to Stellar Multi-Currency Insurance Plan II] Flexible choice of withdrawal currency: SunWallet supports currency exchange in up to 17 currencies, enabling easier 24/7 policy management From now until July 31, 2025, Clients successfully apply upgraded series of savings insurance products can enjoy the following offers: SunJoy Global Insurance Plan II/SunGift Global Insurance Plan II (5-pay) - Up to 74% of the annualized first year premium#; SunJoy Global Insurance Plan II/SunGift Global Insurance Plan II (2-pay) - Up to 10% of the annualized first year premium#; Stellar Multi-Currency Insurance Plan II - Up to 93% of the annualized first year premium^. Remarks 1 "Market-leading" refers to the services provided by Sun Life, the data of savings plans of new policies offered by composite and long-term insurers on the Register of Authorised Insurers of the Insurance Authority, and market conditions as of July 1, 2025. 2 This is an administrative arrangement and is not part of the product features. Please see the relevant leaflet and prescribed form for more details on the policy owner rights and the restrictions applicable to the designation of Contingent Policy Owner and the designation of Interim Policy Owner for the Contingent Policy Owner. 3 If this option is selected, the beneficiary must be a living individual. 4 Requests are subject to our approval. The New Policy will take effect from the Continuation Option Effective Date. a. The Policy Date and the policies years of the New Policy will be the same as the Original Policy. b. The Notional Amount, total premiums due and paid, outstanding amount of any loans and interest, and the policy values of the Original Policy, including Guaranteed Cash Value, accumulated Reversionary Bonus (if any), Terminal Bonus (if any) and the amount in the Value Lock-in Account (if any) will be allocated to the New Policy according to the designated percentage to the corresponding beneficiary according to the policy owner's instructions. c. There is no cooling-off period for the New Policy, and d. For the purpose of counting the applicable period under the Incontestability provision, the relevant period will commence from the Continuation Option Effective Date for the New Insured. 5 The beneficiary will become both the New Insured and the new policy owner if (i) the designated insured who is also the policy owner has died; or (ii) the designated insured is not the policy owner, and the policy owner and the designated insured die at the same time; or (iii) the policy owner dies within 14 days after the death of the designated insured. 6 He/she must be the Designated Insured. 7 The Notional Amount after the Value Lock-in Option is exercised cannot be less than the minimum amount requirement. 8 The irrevocable beneficiary(ies) (if any) and the assignee (if any) must agree in writing to the requested designation of (a) the Incapacity Benefit Recipient; and (b) the Incapacity Benefit Percentage. Any existing Incapacity Benefit Recipient will be automatically revoked when (a) the policy owner designate a new Incapacity Benefit Recipient and the policy owner's request is approved by us; (b) the policy owner is changed; (c) Sun Life HK has been notified that there is a guardian or committee appointed under the Mental Health Ordinance (Cap. 136 Laws of Hong Kong SAR) (or if there is a guardian or committee appointed under similar laws in another jurisdiction); or (d) Sun Life HK has been notified that the policy owner has an enduring power of attorney covering the policy. In the event that there is a dispute between the Incapacity Benefit Recipient and any other person, including but not limited to the insured's guardian, committee, attorney, beneficiary(ies), assignee or in our reasonable belief that there is such a dispute, Sun Life HK reserves the right to withhold the payment of the Incapacity Benefit until such dispute is resolved. 9 Coma means a state of unconsciousness with no reaction to external stimuli or internal needs persisting continuously with the use of life support systems for a period of at least 1 week and resulting in a neurological deficit, which in our medical officer's opinion is of a permanent nature. 10 Major Head Trauma means major trauma to the head with disturbance of the brain function confirmed by definite diagnosis by a consultant neurologist acceptable to us. The disturbance must result in a permanent bedridden situation or the inability to perform without assistance 3 or more Activities of Daily Living. 11 Paralysis means permanent loss of muscular power of both arms or both legs due to the disorder of the brain and nervous system and confirmed by a Specialist in the relevant medical field. 12 This benefit is subject to maximum amount, terms and conditions, pre-existing conditions and exclusions listed in the policy document. # It includes basic rebate and green offer (guaranteed prepayment interest rate applies and only applicable to policies in United States Dollars). Terms and conditions apply. Please refer to the promotional leaflet for details. ^ It includes basic rebate, Enhanced Rebate and green offer (guaranteed prepayment interest rate applies and only applicable to policies in United States Dollars). Terms and conditions apply. Please refer to the promotional leaflet for details. Hashtag: #SunLife永明 #永明金融 #SunLife #儲蓄保險 #分紅保險 #財富傳承 #萬年青 #星河尊享 #星河傳承 #永越 #身故保障 #後補保單主權人 #保單暫托人 #savingsinsurance #participatinginsurance #wealthlegacy #SunJoy #SunGift #Stellar #deathbenefit #policyowner #contingentpolicyowner #interimpolicyownerThe issuer is solely responsible for the content of this announcement.About Sun LifeSun Life is a leading international financial services organization providing asset management, wealth, insurance and health solutions to individual and institutional Clients. Sun Life has operations in a number of markets worldwide, including Canada, the United States, the United Kingdom, Ireland, Hong Kong, the Philippines, Japan, Indonesia, India, China, Australia, Singapore, Vietnam, Malaysia and Bermuda. As of March 31, 2025, Sun Life had total assets under management of $1.55 trillion. For more information, please visit www.sunlife.com. Sun Life Financial Inc. trades on the Toronto (TSX), New York (NYSE) and Philippine (PSE) stock exchanges under the ticker symbol SLF. Sun Life Financial Inc. is the holding company of Sun Life Assurance Company of Canada. Sun Life Hong Kong Limited is a wholly-owned subsidiary of Sun Life Assurance Company of Canada.
SAN FRANCISCO and SUZHOU, China, June 27, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that China's National Medical Products Administration (NMPA) has approved mazdutide, a first-in-class dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, for chronic weight management in Chinese adults with overweight or obesity. Mazdutide is the world's first dual GCG/GLP-1 receptor agonist approved for weight loss, offering a unique mechanism that enhances weight-loss efficacy while reducing visceral fat and delivering comprehensive metabolic benefits, named by Fierce Pharma as one of the top ten most anticipated drugs globally in 2025. The increasing prevalence of overweight and obesity in China poses an urgent public health challenge requiring immediate intervention. In April 2025, the National Health Commission officially included "Healthy Weight Management Action" in the "Healthy China 2030" initiative. Under the updated plan, the national health authorities aim to build supportive environments for effective weight management, raise public awareness and behavior skills, and promote healthy lifestyles to curb rising rates of overweight and obesity. Aligned with these national priorities and the 2025 weight management campaign, the approval of mazdutide represents a timely and important milestone. Aiming to be an innovative leader in the cardiovascular and metabolic (CVM) disease area, Innovent is committed to accelerating the delivery of this drug to benefit a broad population in China. Mazdutide Scientific and effective treatment options for weight loss are urgently needed in China Overweight and obesity are chronic metabolic diseases characterized by excessive fat accumulation in the body. The pathogenesis of overweight and obesity includes genetic, metabolic, environmental, and behavioral factors. Obesity can significantly increase the risk of various diseases, such as cardiovascular and cerebrovascular, endocrine, specific tumors, respiratory, reproductive, and skeletal diseases, and can seriously affect quality of life[1]. In China, over 500 million adults live with overweight (BMI ≥ 24 kg/m2 and ˂ 28 kg/m2) or obesity (BMI ≥ 28 kg/m2). Nearly 90% of obese adults have comorbidities, including metabolic dysfunction-associated fatty liver disease, which affects around 50% of adults with overweight and over 80% of adults with obesity. The World Obesity Federation (WOF) estimates that obesity costs China around US$283.3 billion in GDP loss in 2020[2]. With such heavy societal burdens, obesity and related chronic diseases have become major public health concerns in China and around the world. In response to the escalating obesity problem, several national policies and clinical guidelines have underscored the need for structured outpatient weight management and earlier pharmacological intervention. The National Health Commission's "Notice on Effective Outpatient Settings and Management of Weight Management" encourages the development of optimized outpatient care models. Additionally, "Guidelines for the Diagnosis and Treatment of Obesity (2024 Edition)" recommended pharmacotherapy when lifestyle interventions fail to meet weight loss goals. The "Guidelines for Long-term Weight Management and Clinical Application of Drugs for Obese Patients (2024 Edition)" issued by the Chinese Society of Endocrinology further advocates for initiating drug treatment early in patients with obesity-related comorbidities. Mazdutide is supported by robust clinical data published in multiple high-impact journals, including Nature, the Lancet sub-journals, and the New England Journal of Medicine. As the first marketed dual GCG/GLP-1 receptor agonist , mazdutide has been recommended by multiple clinical guidelines in China[3],[4],[5],[6] and expert consensus on obesity management on account of its innovative mechanism and solid evidence base. Multiple metabolic benefits of mazdutide in supporting weight management GCG receptors are mainly expressed in the liver, and GCG receptor agonism can inhibit hepatic fat synthesis and promote hepatic lipolysis. As a dual GCG/GLP-1 receptor agonist weight loss drug, mazdutide can deliver significant weight loss efficacy and metabolic benefits such as waist circumstance and liver fat content reductions to adults with overweight or obesity. The approval of mazdutide was mainly based on data from GLORY-1, a Phase 3 pivotal clinical study conducted in Chinese adults with overweight or obesity. The primary endpoint and all key secondary endpoints of the study were successfully achieved in 2024. Results showed that at weeks 32 and 48, the percentage of body weight reduction from baseline and the proportions of participants with a body weight reduction of ≥5%，≥10% and ≥15% in the mazdutide 4 mg group and mazdutide 6 mg group were superior to those of the placebo group. Based on the efficacy estimand, at week 48, the mean percentage changes in body weight relative to baseline in the mazdutide 4 mg, mazdutide 6 mg, and placebo groups were −12.0%, −14.8%, and −0.5%, respectively; The proportion of participants with a body weight reduction ≥ 5% relative to baseline were 73.5%, 82.8%, and 11.5%, respectively; the proportion of participants with a body weight reduction ≥ 15% relative to baseline were 37.0%, 50.6%, and 2.1%, respectively; The mean changes in waist circumference relative to baseline were −9.5 cm, −11.0 cm, and −1.5 cm, respectively. In addition, mazdutide reduced liver fat content in adults with overweight or obesity. Among participants with baseline liver fat content ≥ 10%, the mean percent change from baseline in liver fat content to week 48 were −65.85%, −80.24%, and −5.27% in the mazdutide 4 mg, 6 mg, and placebo groups, respectively. The results of GLORY-1 study have been presented at the American Diabetes Association (ADA) Annual Meeting and published in the New England Journal of Medicine, which have received widespread attention from industry experts and scholars. Mazdutide addresses a critical unmet need in China by offering effective treatment for weight reduction while also improving cardiometabolic indicators in adults with overweight or obesity. Its use may help reduce the long-term societal and economic burdens associated with obesity-related diseases. Professor Linong Ji, the Leading Principal Investigator of GLORY-1, Peking University People's Hospital, stated, "Obesity is a chronic disease that demands a coordinated societal response. With China facing a high prevalence of overweight and obesity, the associated cardiometabolic disease burdens continue to rise. There is an urgent need for weight-loss therapies that are both effective and safe, with proven cardiovascular and metabolic benefits. As the principal investigator of this novel dual GCG/GLP-1 receptor agonist with a unique mechanism of action, I'm proud to see our clinical results recognized by China's national regulatory authority and anticipate its subsequent approval for market launch. My fellow researchers and I hope mazdutide will become a valuable therapeutic option for Chinese adults with overweight or obesity." Dr. Lei Qian from Innovent Biologics, stated, "Mazdutide represents the next-generation dual GCG/GLP-1 receptor agonist. Its clinical development has been made possible by pooling the collective expertise of leading endocrinology experts across China, and its successful approval reflects the NMPA's high recognition of its clinical value and safety. This milestone marks another breakthrough for Innovent in the cardiovascular and metabolic fields. We hope mazdutide will provide another therapeutic option for Chinese adults with overweight or obesity, improve their quality of life, and alleviate societal burdens. Centered on patient needs and innovation, Innovent has established and will continue to expand its rich CVM pipeline with mazdutide as a cornerstone product, aiming to continuously address the public's growing demand for health and quality of life and to serve more patients." About Obesity/Overweight Obesity is a chronic metabolic disease with complex causes, and it serves as a major risk factor for a range of diseases including diabetes, fatty liver disease, cardiovascular and cerebrovascular diseases, kidney disease, joint disorders, sleep-disordered breathing, and cancer. China has the world's largest population of individuals with overweight or obesity, a trend that is likely to rise[7]. Obesity is associated with multiple comorbidities and is a major contributor to reduced life expectancy and quality of life. In 2019, overweight and obesity accounted for 11.1% of deaths from chronic non-communicable diseases in China, nearly doubling from 5.7% in 1990[8]. Despite the chronic nature of obesity and its need for long-term management, treatment options remain limited. While lifestyle interventions remain the cornerstone of treatment, many patients struggle to achieve or maintain meaningful weight reduction. This underscores the urgent need for safe, effective, and sustainable pharmacological interventions. About Mazdutide Innovent entered into an exclusive license agreement with Eli Lilly and Company (Lilly) for the development and potential commercialization of mazdutide, a dual GCG /GLP-1 receptor agonist, in China. As a mammalian oxyntomodulin (OXM) analogue, in addition to the effects of GLP-1 receptor agonists on promoting insulin secretion, lowering blood glucose and reducing body weight, mazdutide may also increase energy expenditure and improve hepatic fat metabolism through the activation of glucagon receptor. Mazdutide has demonstrated excellent weight loss and glucose-lowering effects in clinical studies, as well as reducing waist circumference, blood lipids, blood pressure, serum uric acid, liver enzymes, liver fat content and improved insulin sensitivity. Mazdutide is approved by NMPA for chronic weight management in adults with overweight or obesity*; and mazdutide currently has another NDA accepted for review by NMPA, for glycemia control in adults with type 2 diabetes. Mazdutide has currently conducted seven Phase 3 clinical studies, including: GLORY-1: A Phase 3 clinical study conducted in Chinese adults with overweight of obesity; GLORY-2: A Phase 3 clinical study conducted in Chinese adults with moderately to severely obesity; GLORY-3: A Phase 3 clinical study comparing mazdutide versus semaglutide in Chinese adults with overweight of obesity accompanied metabolic-associated fatty liver disease (MAFLD); GLORY-OSA: A Phase 3 trial in Chinese participants with obstructive sleep apnea (OSA) and obesity; DREAMS-1: A Phase 3 clinical study conducted in Chinese adults with untreated type 2 diabetes; DREAMS-2: A Phase 3 clinical study comparing mazdutide versus dulaglutide in Chinese adults with type 2 diabetes who have poor glycemia control with oral medication; DREAMS-3: A Phase 3 clinical study comparing mazdutide versus semaglutide in Chinese adults with type 2 diabetes and obesity; Among these, GLORY-1, DREAMS-1, and DREAMS-2 have already met their primary endpoints and the other four studies are currently ongoing. In addition, several new clinical studies of mazdutide are initiated or planned, including: A Phase 3 trial in adolescents with obesity; New studies in patients with metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction (HFpEF). *Mazdutide is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial Body Mass Index (BMI) of: BMI ≥ 28 kg/m² (obesity); or BMI ≥ 24 kg/m² (overweight) in the presence of at least one weight-related comorbid condition (e.g., hyperglycemia, hypertension, dyslipidemia, fatty liver, or obstructive sleep apnea syndrome and etc.). About Innovent Biologics Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 16 products in the market. It has 2 new drug applications under regulatory review, 4 assets in Phase 3 or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action" Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn. Statement: Innovent does not recommend the use of any unapproved drug (s)/indication (s). Forward-looking statement This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions. Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect. REFERENCES [1] Multidisciplinary Clinical Consensus on Diagnosis and Treatment of Obesity (2021 edition), Chinese Journal of Endocrinology and Metabolism. 2021;37(11):959-972. [2] Qin X, Pan J. The Medical Cost Attributable to Obesity and Overweight in China: Estimation Based on Longitudinal Surveys. Health Econ. 2016;25(10):1291-1311. doi:10.1002/hec.3217 [3] Guideline for Chronic Weight Management and Clinical Practice of Anti-obesity Medications (2024 version). Chinese Journal of Endocrinology and Metabolism. 2024,40(7): 545-564 [4] Expert Consensus on Weight Management for Type 2 Diabetes Mellitus. International Journal of Endocrinology and Metabolism.2024,44(5):359-370 [5] Expert Consensus on Glucagon-like Peptide-1 Receptor Agonist Analogs Combined with Lifestyle Intervention for Weight Loss (2024 Edition). Chinese Journal of Diabetes, 2024 [6] Interpretation of National Health Commission of the People's Republic of China. National Clinical Practice Guideline on Obesity Management (2024 Edition). Chinese Medical Journal, 2025, *105*(18): 1387-1391. [7] Pan XF, Wang L, Pan A. Epidemiology and determinants of obesity in China. Lancet Diabetes Endocrinol 2021; 9: 373-92 [8] Institute for Health Metrics and Evaluation. Global Health Data Exchange. GBD results tool. http://ghdx.healthdata.org/gbd-resultstool (accessed Jan 10, 2021).
TIANJIN, China, June 27, 2025 /PRNewswire/ -- Cheung Kong Graduate School of Business (CKGSB) Dean and Dean's Distinguished Chair Professor of Finance Li Haitao spoke at the Annual Meeting of the New Champions 2025 of the World Economic Forum, widely known as Summer Davos, in Tianjin, China, for the second year in a row, a testament to the school's thought leadership and acknowledgement. This year's Summer Davos focused on entrepreneurship for a new era. As the most active Chinese business school this year at the Summer Davos, CKGSB contributed to the discourse on multiple meaningful topics including AI reshaping global competition and entrepreneurship in the new era. In the session broadcast live globally on June 26, "Understanding China's approach to AI," Dean Li joined leading voices to explore China's advantage in developing AI amid re-globalization, industrial possibilities brought by AI, and how AI can propel doing business for good by providing scarce resources. "Only two countries, China and the US, can lead AI revolution in the next decades," emphasized Dean Li. "China has done lots of accumulation for decades with infrastructure, data, talent, and market to establish a unique AI ecosystem. Beyond home appliances, smartphones, and automobiles, humanoid robots have the greatest potential to become a trillion-dollar industry in China. CKGSB aspires to systematically prepare business leaders for what the AI era requires for strategic architecture capabilities and new leadership skills." Moderated by renowned journalist Yang Lan, the panel also featured executives and scholars including Unitree Robotics Founder and CEO Wang Xingxing, Haier CEO Zhou Yunjie, USC Professor of Law Angela Zhang Huyue, and Workera Founder and CEO Kian Katanforoosh. In addition, Dean Li delivered a keynote speech at the session around Gen Z consumers. He noted that with Gen Z's robust purchasing power and authentic passion for eco-conscious consumption, and as more start to evaluate companies' sustainable commitment when making career decisions, companies must build a new collaboration structure where people at all levels get to affect decision making, contribute their own knowledge and jointly create value. Dean Li also participated at the Global University Leaders Meeting, discussing how higher education institutions should shape the future of research through partnerships and continue to serve as engines of innovation. CKGSB also co-hosted CKGSB's 2025 Davos Night in collaboration with Tencent's Tencent News.
A12 藝術空間
Accumulation
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
![AIA Rethink Healthy Ambassador and 7-time award-winning actress Michelle Wai stars in the new GlobalFlexi Savings Insurance Plan campaign
[Watch the campaign video by clicking here]](/images/user_uploaded/171697_34ff20c6820b49aead4544f788e8c76e-800x600.jpeg "AIA Rethink Healthy Ambassador and 7-time award-winning actress Michelle Wai stars in the new GlobalFlexi Savings Insurance Plan campaign
[Watch the campaign video by clicking here]")
